DAVID LONARD to Drug Resistance, Neoplasm
This is a "connection" page, showing publications DAVID LONARD has written about Drug Resistance, Neoplasm.
Connection Strength
0.420
-
Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nat Commun. 2021 02 15; 12(1):1022.
Score: 0.123
-
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. Sci Rep. 2019 10 22; 9(1):15099.
Score: 0.113
-
Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers. Biochem Pharmacol. 2017 09 15; 140:1-7.
Score: 0.094
-
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLoS One. 2024; 19(4):e0289902.
Score: 0.039
-
The REG? inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cells. Nat Commun. 2020 08 06; 11(1):3904.
Score: 0.030
-
HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Res. 2016 Mar 15; 76(6):1463-75.
Score: 0.022